Results 131 to 140 of about 7,177,989 (337)

Artificial Intelligence for Benign Esophageal Stricture Dilation: An Evidence‐Transferability Framework and Safety‐First Roadmap

open access: yesAI &Innovation, EarlyView.
ABSTRACT Background Endoscopic dilation is first‐line therapy for symptomatic benign esophageal strictures but remains operator‐dependent. Artificial intelligence (AI) could support assessment, risk stratification, and documentation; however, evidence from adjacent tasks is often mistaken for procedure‐specific validation.
Ahmed A. Salman, Mohamed A. Salman
wiley   +1 more source

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

open access: yesBMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu   +5 more
wiley   +1 more source

Genomic Analyses Reveal Mutational Signatures and Frequently Altered Genes in Esophageal Squamous Cell Carcinoma

open access: yesAmerican Journal of Human Genetics, 2020
Toidentifygenome-widemutationalsignatures, we performedeither whole-genomesequencing(WGS)or whole-exomesequencing(WES) on104ESCCindividualsandcombinedourdatawiththoseof88previouslyreportedsamples.An APOBEC -mediatedmutationalsignaturein 47% of 192 tumors
Ling Zhang   +66 more
semanticscholar   +1 more source

Esophageal Squamous Cell Cancer: Pathogenesis and Epidemiology

open access: yes, 2023
Esophageal cancer is a highly lethal disease. Despite an increasing incidence of adenocarcinoma in last decades, squamous cell carcinoma remains the predominant cell type worldwide. The majority of squamous cell cancers are from the East.
Law, S, Wong, C
core   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

open access: yesBMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo   +9 more
wiley   +1 more source

Functional analysis of N-MYC downstream regulated gene 1 (NDRG1) in Oesophageal squamous cell carcinoma [PDF]

open access: yes, 2009
Oesophageal squamous cell carcinoma (OSCC) ranks as one of the deadliest tumours with a high incidence in developing countries in the areas of Southern Africa, Middle East and Far East.
Wei, Wei
core   +1 more source

Multi-faceted epigenetic dysregulation of gene expression promotes esophageal squamous cell carcinoma

open access: yesNature Communications, 2020
Epigenetic landscapes can shape physiologic and disease phenotypes. We used integrative, high resolution multi-omics methods to delineate the methylome landscape and characterize the oncogenic drivers of esophageal squamous cell carcinoma (ESCC).
W. Cao   +29 more
semanticscholar   +1 more source

Intratumoral heterogeneity of esophageal squamous cell carcinoma [PDF]

open access: yesJournal of Thoracic Disease, 2017
The advent of large scale genome characterization led to rapidly increasing knowledge of genetic landscapes of malignancies in recent years. Besides a difference in quantity of mutations between different entities, studies revealed as well a difference in the amount of mutations in varying locations of a single neoplastic lesion: the relation of ...
openaire   +2 more sources

Model‐based clinical pharmacology profiling of subcutaneous nivolumab in renal cell carcinoma: Bridging to alternative dosing regimens and indications

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
A novel model‐informed drug development (MIDD) approach was employed to derive the coprimary endpoints (time‐averaged serum concentration over 28 days [Cavgd28] and minimum serum concentration at steady state [Cminss]) of the phase III CheckMate 67T study (NCT04810078).
Yue Zhao   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy